Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.22 USD | +1.98% | +0.42% | -18.51% |
Apr. 15 | Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024 | CI |
Mar. 27 | Aura Biosciences Shares Rise Following Q4 Results | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 496 | 388.9 | 436.4 | 357.6 | - | - |
Enterprise Value (EV) 1 | 496 | 388.9 | 436.4 | 357.6 | 357.6 | 357.6 |
P/E ratio | -10.7 x | -5.36 x | -4.59 x | -3.6 x | -3.5 x | -3.24 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | -14.4 x | -6.45 x | - | -3.69 x | -3.25 x | -2.86 x |
FCF Yield | -6.96% | -15.5% | - | -27.1% | -30.8% | -35% |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 29,211 | 37,040 | 49,260 | 49,533 | - | - |
Reference price 2 | 16.98 | 10.50 | 8.860 | 7.220 | 7.220 | 7.220 |
Announcement Date | 3/23/22 | 3/15/23 | 3/27/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -35.25 | -60.3 | -84.99 | -104.2 | -102.9 | -119 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -35.25 | -58.76 | -76.27 | -91.4 | -97.35 | -114.8 |
Net income 1 | -22.21 | -46.19 | -58.76 | -76.41 | -102.5 | -119 | -143.4 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -5.990 | -1.581 | -1.960 | -1.930 | -2.006 | -2.065 | -2.230 |
Free Cash Flow 1 | - | -34.54 | -60.3 | - | -97 | -110 | -125 |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 10/8/21 | 3/23/22 | 3/15/23 | 3/27/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -8.895 | -11.63 | -12.81 | -13.82 | -16.06 | -17.61 | -19.44 | -20.28 | -20.49 | -24.78 | -24.94 | -25.8 | -26.41 | -27.05 | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -8.838 | -11.63 | -12.84 | -13.47 | -15.9 | -16.56 | -17.47 | -18.3 | -18.51 | -21.99 | -22.4 | -23.2 | -23.5 | -23.6 | - |
Net income 1 | -12.51 | -12.95 | -12.84 | -13.47 | -15.9 | -16.56 | -17.47 | -18.3 | -18.51 | -22.13 | -24.06 | -25.07 | -26.11 | -27.27 | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.2833 | -0.6700 | -0.4400 | -0.4600 | -0.5400 | -0.5200 | -0.4600 | -0.4800 | -0.4800 | -0.5000 | -0.4860 | -0.5000 | -0.5140 | -0.5080 | -0.5800 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/24/21 | 3/23/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/15/23 | 5/11/23 | 8/9/23 | 11/9/23 | 3/27/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -34.5 | -60.3 | - | -97 | -110 | -125 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | 0.9 | 0.9 | 1 |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 10/8/21 | 3/23/22 | 3/15/23 | 3/27/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.51% | 358M | |
+1.51% | 42.75B | |
+48.15% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- AURA Stock
- Financials Aura Biosciences, Inc.